Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Instil Bio, Inc.NASDAQ: TIL

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $12K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $24K. Over 3 fiscal years it compounded at -55.3% a year.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $12K or moves back toward the trailing-twelve-month quarterly average of $6K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12K— QoQ
Last fiscal yearDec 2025
$534K— YoY
LTMMar 2026
$24K-96.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-55.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
534K USD
Year-over-year change
—

Cost of Revenue vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -96.8% is the 7th highest of 8, against a peer median of -26.6%.
  • Over three fiscal years its annual growth of -55.3% compares with a peer median of -41.9%.
TIL Competitors
Cost of Revenue for TIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$711K USD+14.3%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$151K USD———
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$119.31K CAD-26.6%-38.5%—
SRZNSurrozen, Inc.LTM Mar 2026$65K USD-83.2%-45.2%0.9%
TILInstil Bio, Inc.LTM Mar 2026$24K USD-96.8%-55.3%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$5K USD-100.0%-71.8%—
Peer median (excluding TIL) —-26.6%-41.9%106.0%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue05.99M00534K
Gross Profit0(5.99M)00(534K)
Gross Margin—————
Research & Development107.25M141.06M39.6M11.84M10M
Selling, General & Admin51.31M62.24M47.55M44.21M27.22M
Operating Expenses155.56M200.18M159.17M73.54M52.37M
Depreciation & Amortization2.75M5.99M4.76M3.61M534K
EBITDA(152.51M)(217.38M)(147.12M)(62.53M)(65.01M)
EBITDA Margin—————
Operating Income(155.56M)(206.17M)(159.17M)(73.54M)(52.91M)
Operating Margin—————
Interest Income80K3.66M8.87M6.99M3.86M
Interest Expense01.88M5.21M8.99M5.83M
Other Income / Expenses(1.2M)(19.08M)3.08M(594K)(18.47M)
Income Before Tax(156.76M)(225.25M)(156.09M)(74.14M)(71.37M)
Pre-Tax Margin—————
Income Tax Expense39K(2.07M)000
Net Income(156.79M)(223.18M)(156.09M)(74.14M)(71.37M)
Net Margin—————
EPS (Basic)(29.60)(34.46)(24.00)(11.39)(10.70)
EPS (Diluted)(29.60)(34.46)(24.00)(11.39)(10.70)
Weighted Avg Shares5.3M6.48M6.5M6.51M6.67M
Weighted Avg Shares (Diluted)5.3M6.48M6.5M6.51M6.67M

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.